ReviewThe Lancet regional health. Europe2025
Quick buys for prevention and control of noncommunicable diseases.
Review in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Global trends in national alcohol control policies between 2010 and 2019.JHEP reports : innovation in hepatology · 2026Article
- The role of alcohol control policy on the level of alcohol consumption in member states of the Association of Southeast Asian Nations 2000-2022: identifying trends and country clusters for further analyses.Journal of global health · 2026Article
- Assessing the progress in implementing population-based policies to reduce the burden of noncommunicable diseases in Eastern Europe and Central Asia, 2010-2024.Health policy and planning · 2026Article
- Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.The Lancet regional health. Europe · 2026Review
- Beyond the funding crisis: what the next European budget means for public health.European journal of public health · 2026Article
- European Code Against Cancer 5th edition: 14 ways you can help prevent cancer.The Lancet regional health. Europe · 2026Review
- Comparing decentralized machine learning and AI clinical models to local and centralized alternatives: a systematic review.NPJ digital medicine · 2026Article
- From commitment to capacity: strengthening Europe's public health response to cardiovascular disease and diabetes through life-course prevention.Public health reviews · 2026Article
- Full alcohol marketing ban and adolescent drinking patterns: a repeated cross-sectional analysis comparing Lithuania with other EU countries.BMJ public health · 2026Article
- Does the Nutri-Score 2023 algorithm provide consistent classification across European food supplies? A cross-sectional study using branded food composition data from 14 countries.BMJ public health · 2026Article
- Global Trends in Alcohol Control Policies Between 2010-2019.Research square · 2025Article
- Health and health equity in policymaking across sectors: Identifying opportunities and challenges in implementing Health in All Policies.Scandinavian journal of public health · 2025Article
- Are marketing bans on alcoholic beverages a quick buy?-authors' reply.The Lancet regional health. Europe · 2025Article
- Are marketing bans on alcoholic beverages a quick buy?The Lancet regional health. Europe · 2025Article
- Cardiometabolic Phenotypes and Dietary Patterns in Albanian University-Enrolled Young Adults: Cross-Sectional Findings from theNutrients · 2025Article
- Advancing Europe's non-communicable diseases agenda through cross-national collaboration: translating WHO-Europe findings into actionable strategies.The Lancet regional health. Europe · 2025Article
- Preventing Multimorbidity: Moving Beyond the Single Disease Lens.International journal of public health · 2025Article
- Impact of health promotion strategies on HPV vaccination uptake: A descriptive epidemiological study (2019-2024).PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Despite their established effectiveness, uptake of the WHO best buys for tackling non-communicable diseases (NCDs) has been uneven and disappointing. Here we introduce the "quick buys", an evidence-based set of cost-effective interventions with measurable public health impacts within five years. We reviewed 49 interventions previously established as cost-effective (<$I20,000 per disability-adjusted life-year averted) to identify the earliest possible detectable effect on high-level population health targets. Using a strict evidence hierarchy, including Cochrane and systematic reviews, we estimated the effects of each intervention against global targets agreed upon by countries. Quick buys were defined as those interventions that could exhibit measurable effects within 5 years, aligning with average electoral cycles in across the WHO European Region. Of the 49 interventions, 25 qualified as quick buys, including those relating to tobacco (n = 5), alcohol (n = 4), unhealthy diet (n = 3), physical inactivity (n = 1), cardiovascular disease (n = 3), diabetes (n = 4), chronic respiratory disease (n = 1), and cancer (n = 4). These findings not only offer guidance to policymakers deciding on interventions that align with short-term political cycles but also have the potential to accelerate progress to global health targets, particularly the 2030 Sustainable Development Goal of reducing premature NCD mortality by one-third.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.